A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results?

摘要: BACKGROUND: The use of adjuvant therapy for resectable gastric adenocarcinoma has become standard care since the publication Intergroup 0116 data. aims this study were to (1) assess current practice patterns in cancer treatment, and (2) determine effect increasing chemoradiotherapy on survival patients with cancer. PATIENTS AND METHODS: Data from Oregon State Cancer Registry abstracted demographics, disease stage, resection type, number lymph nodes resected, (CRT), 1996-2006. Patients stages IB-III divided into cohorts treated through year 2001 (Group 1) or after 2). Chemoradiotherapy between groups was compared chi-square test. Univariate multivariate analyses performed. Binary logistic regression determined predictors receipt CRT. RESULTS: A total 308 met criteria. Adjuvant employed 17.0% cases Group 1 vs. 36.8% 2 (P < .001). Tumor tumor location, American Joint Committee (AJCC) stage independent both univariate analyses. In retrospective analysis, a modest benefit associated CRT, but did not reach statistical significance. Independent CRT included age, AJCC N2 disease, treatment era. CONCLUSIONS: While increased data, 63.2% potentially eligible receive Future efforts should focus identifying removing barriers following adenocarcinoma.